Table 2.
New starts on LAI SGAs among study sample: 2007–2015 with comparison to 2011
| Year | Patients with any antipsychotics | New starts on LAI risperidone |
New starts on LAI paliperidone |
New starts on SGA LAIs (excluding LAI risperidone and paliperidone)+ |
New starts on all LAI SGAs |
||||
|---|---|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | N | % | ||
| 2007 | 67,023 | 1574 | 2.3^ | 0 | 0 | 0 | 0 | 1574 | 2.3^ |
| 2008 | 68,616 | 1542 | 2.2^ | 0 | 0 | 0 | 0 | 1542 | 2.2^,# |
| 2009 | 70,468 | 1543 | 2.2^ | 30 | 0^ | 0 | 0 | 1573 | 2.2^,# |
| 2010 | 71,346 | 1383 | 1.9# | 560 | 0.8^,# | 1 | 0 | 1944 | 2.7^,# |
| 2011* | 72,000 | 1244 | 1.7 | 1338 | 1.9 | 1 | 0 | 2583 | 3.6 |
| 2012 | 72,410 | 1102 | 1.5 | 1645 | 2.3^ | 3 | 0 | 2750 | 3.8^ |
| 2013 | 72,535 | 1100 | 1.5 | 1890 | 2.6^,# | 23 | 0 | 3013 | 4.2^,# |
| 2014 | 72,371 | 988 | 1.4^ | 2090 | 2.9^,# | 73 | 0.1 | 3151 | 4.4^,# |
| 2015 | 73,008 | 771 | 1.1^,# | 2503 | 3.4^,# | 180 | 0.2 | 3454 | 4.7^,# |
| All years | 115,172 | 11,929 | 10.0% | 13,229 | 11.1% | 566 | 0.5% | 25,724 | 21.5% |
| Change | 5985 | − 803 | − 1.2% | 2503 | 3.4% | 180 | 0.25% | 1880 | 2.4% |
| Percent change | 8.9% | − 51.0% | − 52.2% | –- | –- | –- | –- | 119.4% | 104.3% |
*Used as the reference year to define pre- and post-publication of a cooperative study (CSP#555)
^Statistically significant difference as compared to the reference year
#Statistically significant difference when compared to the previous year (excluding comparisons with the reference year)
+Sample was too small to conduct a statistical model